NSCLC ADENOCARCINOMA
Clinical trials for NSCLC ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new NSCLC ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for NSCLC ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo targets Hard-to-Treat cancers with genetic weakness
Disease control Recruiting nowThis early-stage trial is testing a new drug called IDE892, alone or with another drug (IDE397), in people with advanced solid tumors that have a specific genetic deletion (MTAP). The study aims to find safe doses and see if the drugs shrink tumors. It includes 260 adults with ca…
Matched conditions: NSCLC ADENOCARCINOMA
Phase: PHASE1 • Sponsor: IDEAYA Biosciences • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New Antibody-Drug conjugate targets Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial tests MGC028, a drug that delivers a cancer-killing agent directly to tumor cells. About 124 adults with advanced lung, bile duct, pancreatic, or colorectal cancers that have stopped responding to standard treatments will receive the drug every three weeks.…
Matched conditions: NSCLC ADENOCARCINOMA
Phase: PHASE1 • Sponsor: MacroGenics • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC